Hospitalizaciones por cáncer de cuello de útero en la Comunidad de Madrid, 1999-2002

Muñoz, 2006, Chapter 1: HPV in the etiology of human cancer, Vaccine, 24, S1, 10.1016/j.vaccine.2006.05.115 Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5 Version 2.0. Lyon: IARCPress; 2004. Documento de consenso de las sociedades científicas. Vacunas profilácticas frente a VPH. Enero 2007. Disponible en: http://www.vacunasaep.org/pdf/2007/consenso_sociedades_vacuna%20_vph.pdf. Bray, 2005, Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening, Cancer Epidemiol Biomarkers Prev., 14, 677, 10.1158/1055-9965.EPI-04-0569 Suris, 1998, Survival in cervical cancer, Eur J Gynaecol Oncol., 19, 11 Llorca, 2006, Cervical cancer mortality is increasing in Spanish women younger than 50, Cancer Lett., 240, 36, 10.1016/j.canlet.2005.08.021 Dirección General de la Agencia de Calidad del Sistema Nacional de Salud. Secretaría General de Sanidad. Ministerio de Sanidad y Consumo. Estrategia en cáncer del Sistema Nacional de Salud, 2006. Disponible en: http://www.e-oncologia.org/oncologiaV4/scorm/recursos/materiales/noscorm/curs_cervix280408/intro/mc/estrategia.pdf. Brown, 1996, Screening pattern for cervical cancer: how best to reach the unscreened population, J Natl Cancer Inst Monogr., 21, 7 Subdirección General de Desarrollo. Instituto Nacional de Salud. Ministerio de Sanidad y Consumo. Conjunto Mínimo Básico de Datos. Hospitales de Insalud 2001. Disponible en: http://www.ingesa.msc.es/estadEstudios/documPublica/pdf/CMBD-2001.pdf. Rivero Cuadrado, 2000, El conjunto mínimo básico de datos en el SNS: inicios y desarrollo actual. Revista Fuentes Estadísticas, Fuentes españolas, 49 Ministerio de Sanidad y Consumo. Análisis y desarrollo de los GDR en el Sistema Nacional de Salud 1999. Disponible en: www.msps.es/estadEstudios/estadisticas/docs/analisis.pdf. Bosch, 2003, Chapter 1: Human papillomavirus and cervical cancer – Burden and assessment of causality, J Natl Cancer Inst Monogr., 31, 3, 10.1093/oxfordjournals.jncimonographs.a003479 Parkin, 2002 De Sanjosé, 2003, Cervical human papillomavirus infection in the female population in Barcelona, Spain, Sex Transm Dis., 30, 788, 10.1097/01.OLQ.0000080177.82204.E0 Encuesta de hábitos sexuales. Instituto Nacional de Estadística. 2004 Disponible en: http://www.ine.es/prensa/np336.pdf. Huff, 1996, Using hospital discharge data for disease surveillance, Public Health Rep., 111, 78 Gil, 2004, Epidemiology of severe varicella-zoster virus infection in Spain, Vaccine., 22, 3947, 10.1016/j.vaccine.2004.04.004 Gil, 2004, Burden of hospitalizations attributable to rotavirus infection in children in Spain, period 1999–2000, Vaccine., 22, 2221, 10.1016/j.vaccine.2003.11.037 Gil, 2002, Epidemiology of pneumonia hospitalizations in Spain, 1995–1998, J Infection., 44, 84, 10.1053/jinf.2002.0966 Penberthy, 2003, Using hospital discharge files to enhance cancer surveillance, Am J Epidemiol., 158, 27, 10.1093/aje/kwg108 Middleton, 2000, Accuracy of hospital discharge data for cancer registration and epidemiological research in Northern Ireland, Cancer Causes Control., 11, 899, 10.1023/A:1026543100223 Institut National du Cancer. Analyse économique des côuts du cancer en France. Etudes et expertises. Disponible en: http://www.e-cancer.fr. Castellsagué, 2008, Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH) tipos 6, 11, 16 y 18 en las enfermedades asociadas a VPH en España, Prog Obstet Ginecol., 51, 520, 10.1016/S0304-5013(08)72326-4 Castellsagué, 2009, Epidemiology and costs of screening and management of precancerous lesions of the cervox in Spain, J Low Genit Tract Dis., 13, 38, 10.1097/LGT.0b013e318182cd89 Wallboomers, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J Pathol., 189, 12, 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F Bosch, 2002, The causal relation between human papillomavirus and cervical cancer, J Clin Pathol., 55, 244, 10.1136/jcp.55.4.244 Insinga, 2004, The health care costs of cervical human papillomavirus-related disease, Am J Obstet Gynecol., 191, 114, 10.1016/j.ajog.2004.01.042 Schiller, 2004, Delivering on the promise: HPV vaccines and cervical cancer, Nat Rev Microbiol., 2, 343, 10.1038/nrmicro867 Mandelblatt, 2002, Benefits and costs of using HPV testing to screen for cervical cancer, JAMA., 287, 2372, 10.1001/jama.287.18.2372 Sherman, 2003, Future directions in cervical pathology, J Natl Cancer Inst Monogr., 31, 72, 10.1093/oxfordjournals.jncimonographs.a003486 Sanders, 2003, Cost effectiveness of a potential vaccine for human papillomavirus, Emerg Infect Dis., 9, 37, 10.3201/eid0901.020168 Kulasingam, 2003, Potential health and economic impact of adding a human papillomavirus vaccine to screening programs, JAMA., 290, 781, 10.1001/jama.290.6.781